S with or without a-fetoprotein has served as a standard surveillance tool for hepatocellular carcinoma (HCC). Attempts have been made to overcome the suboptimal detection rates and false referral rates of US. The Japan Society of Hepatology suggests use of contrast material-enhanced CT or MRI as another optional strategy (1). A recent study reported that screening using MRI with liver-specific contrast material resulted in a higher HCC detection rate and a lower false-positive rate when compared with those attained with US screening (2). Still, questions remain regarding the availability, accessibility, and cost-effectiveness of such advanced imaging modalities that should be underlined in the surveillance setting (3-5). Use of a US contrast agent can be a viable option, as it can be simply added to the pre-established surveillance program using B-mode US. The pure blood pool US contrast agents have not been recommended in the surveillance setting because they can be used only for vascular phase (arterial and portal venous phases) imaging, the duration of which might not be sufficient to examine the